Clinical use of factor VIII and factor IX concentrates.
作者信息
Morfini Massimo, Coppola Antonio, Franchini Massimo, Di Minno Giovanni
机构信息
Agency for Haemophilia, Department of Emergency and Reception, Careggi University Hospital, Florence, Italy.
Regional Reference Centre for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
出版信息
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
Abstract
摘要
相似文献
1
Clinical use of factor VIII and factor IX concentrates.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
2
Prophylaxis for adults with haemophilia: one size does not fit all.
Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11.
3
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
Haemophilia. 2014 Sep;20(5):e362-4. doi: 10.1111/hae.12487. Epub 2014 Aug 25.
4
Prophylaxis in haemophilia should be life-long.
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
5
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
6
Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
JAMA. 1984 Jan 6;251(1):67.
7
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.
8
Maintenance of treatment logs by haemophilia patients.
Haemophilia. 2010 May;16(3):545-7. doi: 10.1111/j.1365-2516.2009.02169.x. Epub 2009 Dec 29.
9
[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
Nihon Ketsueki Gakkai Zasshi. 1982 Sep;45(5):987-92.
10
Sodium content in products used to treat haemophilia.
Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26.
引用本文的文献
1
Nonfactor Therapies in Hemophilia A: An Essential Drug Entity.
Cureus. 2024 Oct 3;16(10):e70763. doi: 10.7759/cureus.70763. eCollection 2024 Oct.
2
Pain in Hemophilia: Unexplored Role of Oxidative Stress.
Antioxidants (Basel). 2022 Jun 3;11(6):1113. doi: 10.3390/antiox11061113.
3
Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection.
Front Public Health. 2022 May 19;10:893770. doi: 10.3389/fpubh.2022.893770. eCollection 2022.
4
In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
Eur J Clin Pharmacol. 2022 Feb;78(2):237-249. doi: 10.1007/s00228-021-03173-2. Epub 2021 Oct 15.
5
Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.
Ther Adv Hematol. 2020 Oct 20;11:2040620720966888. doi: 10.1177/2040620720966888. eCollection 2020.
6
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.
Clin Pharmacokinet. 2021 Jan;60(1):1-16. doi: 10.1007/s40262-020-00936-5.
7
Supramolecular Aptamers on Graphene Oxide for Efficient Inhibition of Thrombin Activity.
Front Chem. 2019 May 16;7:280. doi: 10.3389/fchem.2019.00280. eCollection 2019.
8
Hemophilia trials in the twenty-first century: Defining patient important outcomes.
Res Pract Thromb Haemost. 2019 Mar 12;3(2):184-192. doi: 10.1002/rth2.12195. eCollection 2019 Apr.
9
Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.
Clin Appl Thromb Hemost. 2018 Jul;24(5):741-748. doi: 10.1177/1076029617721011. Epub 2017 Jul 28.
10
Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s582-8. doi: 10.2450/2014.0087-14s.
本文引用的文献
1
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.
Haemophilia. 2014 Mar;20(2):e128-35. doi: 10.1111/hae.12334.
2
Defining severity of hemophilia: more than factor levels.
Semin Thromb Hemost. 2013 Oct;39(7):702-10. doi: 10.1055/s-0033-1354426. Epub 2013 Sep 11.
3
Tailored versus standard dose prophylaxis in children with hemophilia A.
Semin Thromb Hemost. 2013 Oct;39(7):711-22. doi: 10.1055/s-0033-1354419. Epub 2013 Sep 10.
4
Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
Semin Thromb Hemost. 2013 Oct;39(7):752-66. doi: 10.1055/s-0033-1356715. Epub 2013 Sep 10.
5
Hemophilia a and hemophilia B: different types of diseases?
Semin Thromb Hemost. 2013 Oct;39(7):697-701. doi: 10.1055/s-0033-1353996. Epub 2013 Sep 8.
6
Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities.
Semin Thromb Hemost. 2013 Oct;39(7):794-802. doi: 10.1055/s-0033-1354424. Epub 2013 Sep 8.
7
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.
8
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates.
Transfusion. 2013 May;53(5):1143-4. doi: 10.1111/trf.12153.
9
Treatment of hemophilia B: focus on recombinant factor IX.
Biologics. 2013;7:33-8. doi: 10.2147/BTT.S31582. Epub 2013 Feb 12.
10
Factor VIII products and inhibitor development in severe hemophilia A.
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
Zotero 插件